id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308110-cco3aq4n	Okamoto, Mika	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro	2020-07-30		.txt	text/plain	2689	148	51	In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 μM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection. Since not only the inhibition of viral replication but also the control of excessive immune activation is mandatory to save COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.	./cache/cord-308110-cco3aq4n.txt	./txt/cord-308110-cco3aq4n.txt